These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy. Banda CG; Dzinjalamala F; Mukaka M; Mallewa J; Maiden V; Terlouw DJ; Lalloo DG; Khoo SH; Mwapasa V Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150465 [TBL] [Abstract][Full Text] [Related]
12. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Maganda BA; Ngaimisi E; Kamuhabwa AA; Aklillu E; Minzi OM Malar J; 2015 Apr; 14():179. PubMed ID: 25906774 [TBL] [Abstract][Full Text] [Related]
13. Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients. Mhandire D; Lacerda M; Castel S; Mhandire K; Zhou D; Swart M; Shamu T; Smith P; Musingwini T; Wiesner L; Stray-Pedersen B; Dandara C OMICS; 2015 Sep; 19(9):553-62. PubMed ID: 26348712 [TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients. Chou M; Bertrand J; Segeral O; Verstuyft C; Borand L; Comets E; Le Tiec C; Becquemont L; Ouk V; Mentre F; Taburet AM Antimicrob Agents Chemother; 2010 Oct; 54(10):4432-9. PubMed ID: 20696882 [TBL] [Abstract][Full Text] [Related]
15. Occurrence of CYP2B6 516G>T polymorphism in patients with ARV-associated hepatotoxicity. Singh H; Lata S; Dhole TN; Gangakhedkar RR Mol Genet Genomic Med; 2019 Apr; 7(4):e00598. PubMed ID: 30864294 [TBL] [Abstract][Full Text] [Related]
16. Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults. Byakika-Kibwika P; Lamorde M; Okaba-Kayom V; Mayanja-Kizza H; Katabira E; Hanpithakpong W; Pakker N; Dorlo TP; Tarning J; Lindegardh N; de Vries PJ; Back D; Khoo S; Merry C J Antimicrob Chemother; 2012 May; 67(5):1217-23. PubMed ID: 22316571 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic properties of the antimalarial combination therapy artemether-lumefantrine in normal-weight, overweight and obese healthy male adults. Sugiarto SR; Page-Sharp M; Drinkwater JJ; Davis WA; Salman S; Davis TME Int J Antimicrob Agents; 2022 Jan; 59(1):106482. PubMed ID: 34818520 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial. Kakuda TN; DeMasi R; van Delft Y; Mohammed P HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978 [TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 2B6 genetic variants are associated with plasma nevirapine levels and clinical response in HIV-1 infected Kenyan women: a prospective cohort study. Oluka MN; Okalebo FA; Guantai AN; McClelland RS; Graham SM AIDS Res Ther; 2015; 12():10. PubMed ID: 25878720 [TBL] [Abstract][Full Text] [Related]
20. Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children. Parikh S; Kajubi R; Huang L; Ssebuliba J; Kiconco S; Gao Q; Li F; Were M; Kakuru A; Achan J; Mwebaza N; Aweeka FT Clin Infect Dis; 2016 Aug; 63(3):414-22. PubMed ID: 27143666 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]